A newly identified mechanism driving the growth of bowel and liver cancers offers a potential new avenue for treatment, particularly for those cancers proving resistant to existing therapies. Researchers have pinpointed a protein, nucleophosmin (NPM1), as a key player in how these cancers hijack the body’s natural growth control systems – specifically, the WNT pathway. This isn’t simply a discovery of *what* is happening, but *why* certain cancers are so aggressive and difficult to treat, and importantly, offers a specific target for future drug development.
- NPM1 as a Key Driver: Elevated levels of the NPM1 protein, due to genetic errors in the WNT pathway, are found in bowel and liver cancers.
- Targetable Vulnerability: Blocking NPM1 shows promise in halting cancer growth by disrupting protein production within cancer cells and reactivating tumor suppressors.
- Rising Incidence: Bowel cancer rates, especially in younger adults, are increasing, making new treatment options urgently needed. Scotland faces particularly high rates of both bowel and liver cancer.
The WNT pathway is crucial for regulating cell growth and differentiation. Cancer cells, however, can exploit this pathway, essentially turning on the “growth” signal constantly. This research, stemming from the SpecifiCancer project – a Cancer Grand Challenges initiative – reveals that genetic errors within the WNT pathway lead to increased levels of NPM1. NPM1, normally involved in growth control, appears to be co-opted by the cancer to fuel its proliferation. The significance lies in the specificity; because NPM1 isn’t essential for healthy adult tissues, blocking it presents a potentially safe therapeutic strategy.
This discovery is particularly timely. Recent data from the American Cancer Society, published in The Lancet Oncology, highlights a worrying trend: early-onset bowel cancer is rising globally, and at a faster rate in young women in Scotland and England. Scotland already experiences some of the highest rates of both bowel and liver cancer in the UK, with approximately 4,200 new bowel cancer diagnoses and 670 liver cancer deaths annually. Existing treatments, while effective for some, are limited for others, creating a critical need for innovative approaches.
The Forward Look
The immediate next step is the development of medical treatments specifically designed to block the production of the NPM1 protein. Researchers are optimistic that a drug targeting NPM1 could mirror the effectiveness of existing treatments that slow tumor growth, but with a potentially improved safety profile. However, the path from lab discovery to clinical application is lengthy and complex. Expect to see pre-clinical studies focusing on drug candidates within the next 12-18 months, followed by Phase 1 clinical trials to assess safety and dosage in humans.
Beyond bowel and liver cancers, the research team believes the findings could be applicable to other cancers that also hijack the WNT pathway. This suggests a broader potential impact, potentially extending to cancers of the lung, breast, and others. The SpecifiCancer project’s focus on tissue-specific vulnerabilities is a crucial shift in cancer research, moving away from a ‘one-size-fits-all’ approach towards more personalized and targeted therapies. The success of this project underscores the value of large-scale, collaborative research initiatives in tackling complex diseases like cancer.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
